Latest From Dermira Inc.
Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.
Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.
Dermira hopes to move into Phase III quickly with IL-13 inhibitor lebrikizumab, looking at monthly dosing in the maintenance setting. Efficacy in Phase IIb appears similar to Sanofi/Regeneron’s Dupixent.
Galderma’s novel biologic is heading for Phase III studies in moderate-to-severe atopic dermatitis as the race to join Dupixent in an expanding market hots up.
- Large Molecule
- Topical Delivery
- Specialty Pharmaceuticals
- Drug Delivery
- Therapeutic Areas
- Skintelligence Inc.
- North America
- Parent & Subsidiaries
- Dermira Inc.
- Senior Management
Thomas G Wiggans, CEO
Andrew Guggenhime, CFO
Eugene A Bauer, MD, CMO
Chris Griffith, Chief Business & Strategy Officer
Luis Pena, PhD, Chief Dev. Officer
Lori Lyons-Williams, Chief Commercial Officer
- Contact Info
Phone: (650) 421-7200
275 Middlefield Rd.
Menlo Park, CA 94025
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.